Seres醫療 MCRB 深 滬
等待開盤 12-23 09:30:00 美东时间
14.63
-0.350
-2.34%
華盛通- 最 高15.28
- 今 開14.98
- 成交量 7.34万股
- 最 低 14.455
- 昨 收 14.98
- 總市值 1.32亿
- 52周最高 29.98
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 6.53
- 委 比 89.86%
- 總股本 904.65万
- 歷史最高 1040.00
- 量 比 0.75
- 振 幅 5.51%
- 歷史最低 7.20
- 每 手 1
- 風險率 4.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that its management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast will be available on the Company’s website, and a replay will follow. Seres Therapeutics focuses on developing live biotherapeutics to improve outcomes for medically vulnerable popula...
11-24 12:00
美股牛股 | 社区电商平台WeShop上市两日股价翻倍！锂矿公司SGML大涨逾32%
社区电商平台WeShop大涨30%！上市两日股价翻倍；强劲需求驱动近期锂价上涨，锂矿公司SGML隔夜飙涨逾32%>>
11-18 17:39
电话会总结 ｜ Seres(MCRB)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Seres Therapeutics 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **持续经营业务净收入：** 2025年第三季度实现净收入820万美元，而2024年同期为净亏损5100万美元，实现扭亏为盈。这主要得益于出售Voust业务获得2720万美元收益（包括从雀巢收到的2500万美元分期付款），抵消了2250万美元的运营亏损。 **研发费用：** 第三季度为1260万美元，较2024年同期的1650万美元下降23.6%。 **管理费用：** 第三季度为950万美元，较2024年同期的1270万美元下降25
11-06 13:11
Seres Therapeutics Reports Positive Q3 Earnings Call
Seres Therapeutics Inc. (($MCRB)) has held its Q3 earnings call. Read on for th...
11-06 09:20
Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.67 by 40.3 percent. This is a 114.24 percent increase over losses of $(6.60) per share from
11-05 20:04
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics receives $3.6 million from CARB-X to develop an oral liquid formulation of SER-155, targeting high-risk patients like those in intensive care who cannot take capsules. SER-155 has shown promise in reducing bloodstream infections and antibiotic use in allo-HSCT patients. The funding supports expanding access to vulnerable populations at risk of infections and antimicrobial resistance.
10-29 11:00
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics to present Phase 1b data on SER-155 at IDWeek 2025, showcasing a 77% reduction in bloodstream infections and improved microbiological outcomes in allo-HSCT patients. The company is planning a Phase 2 study following FDA feedback and seeking partnerships for development.
10-14 11:00
Seres Therapeutics Announces Actions To Reduce Operating Costs; Reducing Workforce By About 25%; Workforce Reduction To Result In Cash Charges Of $1M-$1.4M
On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to extend its cash runway to provide additional opportunities to advance its strategic
10-04 04:15
Seres Therapeutics Receives FDA Feedback To Finalize Phase 2 Protocol For SER-155 In Preventing BSIs In Allo-HSCT Patients
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for
09-23 19:06
